Sphera Funds Management LTD. decreased its position in shares of Kadmon Holdings Inc (NYSE:KDMN) by 4.0% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,490,000 shares of the company’s stock after selling 62,846 shares during the quarter. Sphera Funds Management LTD. owned approximately 1.32% of Kadmon worth $4,977,000 as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds have also recently made changes to their positions in the company. Voya Investment Management LLC purchased a new stake in Kadmon in the 2nd quarter valued at about $101,000. Metropolitan Life Insurance Co. NY purchased a new stake in Kadmon in the 2nd quarter valued at about $105,000. MetLife Investment Advisors LLC purchased a new stake in Kadmon in the 2nd quarter valued at about $148,000. American International Group Inc. raised its holdings in Kadmon by 46.2% in the 3rd quarter. American International Group Inc. now owns 66,148 shares of the company’s stock valued at $221,000 after buying an additional 20,894 shares during the period. Finally, Dimensional Fund Advisors LP purchased a new stake in Kadmon in the 3rd quarter valued at about $234,000. 71.17% of the stock is currently owned by hedge funds and other institutional investors.
Shares of NYSE:KDMN opened at $2.35 on Friday. The company has a debt-to-equity ratio of 0.32, a quick ratio of 6.58 and a current ratio of 6.64. The stock has a market cap of $272.64 million, a price-to-earnings ratio of -1.65 and a beta of 3.58. Kadmon Holdings Inc has a 1 year low of $1.88 and a 1 year high of $5.86.
KDMN has been the topic of several research analyst reports. HC Wainwright restated a “buy” rating and issued a $25.00 price objective on shares of Kadmon in a report on Monday, November 12th. Zacks Investment Research upgraded shares of Kadmon from a “hold” rating to a “buy” rating and set a $2.75 price objective on the stock in a report on Thursday, November 15th. ValuEngine upgraded shares of Kadmon from a “hold” rating to a “buy” rating in a report on Wednesday, November 7th. Finally, WBB Securities upgraded shares of Kadmon from a “sell” rating to a “hold” rating and set a $2.90 price objective on the stock in a report on Wednesday, October 17th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. Kadmon has an average rating of “Buy” and a consensus price target of $11.13.
COPYRIGHT VIOLATION WARNING: “Sphera Funds Management LTD. Sells 62,846 Shares of Kadmon Holdings Inc (KDMN)” was reported by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another website, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2018/12/08/sphera-funds-management-ltd-sells-62846-shares-of-kadmon-holdings-inc-kdmn.html.
Kadmon Company Profile
Kadmon Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. The company markets and distributes a portfolio of branded generic ribavirin products for chronic hepatitis C virus infection; and distributes products in various therapeutic areas, including tetrabenazine for the treatment of chorea associated with Huntington's disease.
Read More: What is Depreciation?
Receive News & Ratings for Kadmon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon and related companies with MarketBeat.com's FREE daily email newsletter.